These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 35228872)

  • 1. Retraction statement: Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity.
    Clin Transl Immunology; 2022; 11(2):e1378. PubMed ID: 35228872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity.
    Dougall WC; Roman Aguilera A; Smyth MJ
    Clin Transl Immunology; 2019; 8(10):e01081. PubMed ID: 31572609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
    Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
    Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.
    Ahern E; Harjunpää H; O'Donnell JS; Allen S; Dougall WC; Teng MWL; Smyth MJ
    Oncoimmunology; 2018; 7(6):e1431088. PubMed ID: 29872559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity.
    Jiang H; Ni H; Zhang P; Guo X; Wu M; Shen H; Wang J; Wu W; Wu Z; Ding J; Tang R; Zhou S; Chen B; Yu M; Jing H; Liu J
    Oncoimmunology; 2021; 10(1):1943180. PubMed ID: 34239776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion.
    Liu X; Liu L; Ren Z; Yang K; Xu H; Luan Y; Fu K; Guo J; Peng H; Zhu M; Fu YX
    Cell Rep; 2018 Aug; 24(8):2101-2111. PubMed ID: 30134171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific Antibody Binding To RANKL and Osteonectin with Enhanced Localization to the Bone.
    Chen JH; Lin CY; Chen YM; Tian WT; Chu HM; Chang TW
    Mol Pharm; 2017 Nov; 14(11):4113-4120. PubMed ID: 28954509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy.
    Mittal D; Vijayan D; Neijssen J; Kreijtz J; Habraken MMJM; Van Eenennaam H; Van Elsas A; Smyth MJ
    Oncoimmunology; 2019; 8(11):e1648171. PubMed ID: 31646095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities.
    Cui X; Jia H; Xin H; Zhang L; Chen S; Xia S; Li X; Xu W; Chen X; Feng Y; Wei X; Yu H; Wang Y; Zhan Y; Zhu X; Zhang X
    Front Immunol; 2021; 12():778978. PubMed ID: 34925354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.
    Yi M; Zhang J; Li A; Niu M; Yan Y; Jiao Y; Luo S; Zhou P; Wu K
    J Hematol Oncol; 2021 Feb; 14(1):27. PubMed ID: 33593403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibodies in cancer immunotherapy.
    Dahlén E; Veitonmäki N; Norlén P
    Ther Adv Vaccines Immunother; 2018 Feb; 6(1):3-17. PubMed ID: 29998217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade.
    Jeong S; Park E; Kim HD; Sung E; Kim H; Jeon J; Kim Y; Jung UJ; Son YG; Hong Y; Lee H; Lee S; Lim Y; Won J; Jeon M; Hwang S; Fang L; Jiang W; Wang Z; Shin EC; Park SH; Jung J
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Bispecific Immunotoxin Delivered by Human Bone Marrow-Derived Mesenchymal Stem Cells to Target Blood Vessels and Vasculogenic Mimicry of Malignant Gliomas [Retraction].
    Drug Des Devel Ther; 2021; 15():3733-3734. PubMed ID: 34511882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.
    Kotanides H; Li Y; Malabunga M; Carpenito C; Eastman SW; Shen Y; Wang G; Inigo I; Surguladze D; Pennello AL; Persaud K; Hindi S; Topper M; Chen X; Zhang Y; Bulaon DK; Bailey T; Lao Y; Han B; Torgerson S; Chin D; Sonyi A; Haidar JN; Novosiadly RD; Moxham CM; Plowman GD; Ludwig DL; Kalos M
    Cancer Immunol Res; 2020 Oct; 8(10):1300-1310. PubMed ID: 32873605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1.
    Chen W; Pandey M; Sun H; Rolong A; Cao M; Liu D; Wang J; Zeng L; Hunter A; Lin S
    MAbs; 2021; 13(1):1914359. PubMed ID: 33870864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3.
    Rau A; Kocher K; Rommel M; Kühl L; Albrecht M; Gotthard H; Aschmoneit N; Noll B; Olayioye MA; Kontermann RE; Seifert O
    MAbs; 2021; 13(1):1902034. PubMed ID: 33752566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
    Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance.
    Yazaki PJ; Lee B; Channappa D; Cheung CW; Crow D; Chea J; Poku E; Li L; Andersen JT; Sandlie I; Orcutt KD; Wittrup KD; Shively JE; Raubitschek A; Colcher D
    Protein Eng Des Sel; 2013 Mar; 26(3):187-93. PubMed ID: 23175797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.
    Mazor Y; Sachsenmeier KF; Yang C; Hansen A; Filderman J; Mulgrew K; Wu H; Dall'Acqua WF
    Sci Rep; 2017 Jan; 7():40098. PubMed ID: 28067257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.